Legalizing Cannabis
Experiences, Lessons and Scenarios
1st Edition
Published on 30. September 2021
Book
Paperback/Softback
484 pages
978-1-032-17404-4 (ISBN)
Description
Marijuana is the most widely used illegal drug in the world. Over the past couple of decades, several Western jurisdictions have seen reforms in, or changes to, the way cannabis use is being controlled, departing from traditional approaches of criminal prohibition that have dominated cannabis use control regimes for most of the twentieth century. While reform is stalled at the international level, the last decade has seen an acceleration of legislative and regulatory reforms at the local and national levels, with countries no longer willing to bear the human and financial costs of prohibitive policies. Furthermore, legalization models have been implemented in US states, Canada and Uruguay, and are being debated in a number of other countries. These models are providing the world with unique pilot programs from which to study and learn.
This book assembles an international who's who of cannabis scholars who bring together the best available evidence and expertise to address questions such as: How should we evaluate the models of cannabis legalization as they have been implemented in several jurisdictions in the past few years? Which scenarios for future cannabis legalization have been developed elsewhere, and how similar/different are they from the models already implemented? What lessons from the successes and failures experienced with the regulation of other psychoactive substances (such as alcohol, tobacco, pharmaceuticals and "legal highs") can be translated to the effective regulation of cannabis markets?
Legalizing Cannabis will appeal to anyone interested in public health policies and drug policy reform and offers relevant insights for stakeholders in any other country where academic, societal or political evaluations of current cannabis policies (and even broader: current drug policies) are a subject of debate.
This book assembles an international who's who of cannabis scholars who bring together the best available evidence and expertise to address questions such as: How should we evaluate the models of cannabis legalization as they have been implemented in several jurisdictions in the past few years? Which scenarios for future cannabis legalization have been developed elsewhere, and how similar/different are they from the models already implemented? What lessons from the successes and failures experienced with the regulation of other psychoactive substances (such as alcohol, tobacco, pharmaceuticals and "legal highs") can be translated to the effective regulation of cannabis markets?
Legalizing Cannabis will appeal to anyone interested in public health policies and drug policy reform and offers relevant insights for stakeholders in any other country where academic, societal or political evaluations of current cannabis policies (and even broader: current drug policies) are a subject of debate.
Reviews / Votes
"As more countries look to follow evidence-based policies on drug law reform, this book is a welcome addition to the literature on this subject. The "war on drugs" has been a failure. Policy-makers need to know what the alternatives to futile attempts to prohibit drugs are. This book draws on the work of international experts to explore such options." -Rt Hon Helen Clark, Former Prime Minister of New Zealand and Member of the Global Commission on Drug Policy."This is a comprehensive account of the diverse forms that cannabis legalization has taken in recent years, with a separate chapter telling the story and considering the lessons for each case, ranging from Uruguay to Spain to Canada, with US states, Jamaica, the Netherlands and other places in between. Other chapters consider lessons for cannabis control from regulation of alcohol and of tobacco, and from New Zealand's attempts to regulate "legal highs". It's a "must read" for anyone interested in drug policy: its histories are memorable, its interpretations thought-provoking. It's worthwhile reading too for anyone interested in market regulation, in public health policy, or in law reform." - Prof. Robin Room, Centre for Alcohol Policy Research, La Trobe University.
"Professors Decorte, Lenton, and Wilkins have assembled a global all-star team of drug policy researchers for this excellent book. It's a must read for those seeking new insights about the past, present, and future of cannabis legalization." - Dr. Beau Kilmer, coauthor of Marijuana Legalization: What Everyone Needs to Know and director of the RAND Drug Policy Research Center
CHOICE, October 2021 Vol. 59 No. 2:
"From 1964 through 1989 the Single Convention on Narcotic Drugs predicted that non-medical use of cannabis ingredients would be eliminated throughout the world. This prediction never materialized. Instead, the marijuana market in the US alone was estimated at $2.3 billion in 2019 and was expected to reach $4.5 billion in 2020. The UN reported that approximately 250 million people use marijuana globally, making it the most widely used illicit drug in the world. This volume is thus a must-read to understand the legalization trends in other nations, what the nature of future cannabis legalization will be, and how regulation of other drugs such as tobacco and alcohol can inform the necessary regulation of marijuana markets. This book should appeal to public health enthusiasts with an interest in learning about the experiences, lessons, and scenarios of countries around the world that struggle to create public policy to address the rapidly growing international marijuana markets, which have been flourishing recently with the rise in medicinal marijuana use and the growth of recreational marijuana use. This reviewer strongly recommends this volume for anyone interested in understanding the growth of international drug markets." - P. J. Venturelli, Emeritus, Valparaiso University
Summing Up: Highly recommended. Advanced undergraduates through faculty; professionals.
More details
Series
Language
English
Place of publication
London
United Kingdom
Publishing group
Taylor & Francis Ltd
Target group
College/higher education
Postgraduate and Undergraduate
Illustrations
15 s/w Abbildungen
15 Illustrations, black and white
Dimensions
Height: 234 mm
Width: 156 mm
Thickness: 27 mm
Weight
731 gr
ISBN-13
978-1-032-17404-4 (9781032174044)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
Book
02/2020
1st Edition
Routledge
€208.10
Shipment within 10-20 days
E-Book
02/2020
1st Edition
Routledge
€59.49
Available for download
E-Book
02/2020
1st Edition
Routledge
€59.49
Available for download
Persons
Tom Decorte is Professor of Criminology and Director of the Institute for Social Drug Research (ISD) at Ghent University (Belgium). He is co-founder of the Global Cannabis Cultivation Research Consortium (GCCRC). His research interests include patterns of substance use, on the supply side of cannabis markets, and on the implementation of local drug monitoring systems. He has been advisor to a range of organizations on policies to improve public health relating to the use of drugs around the world.
Simon Lenton is a Professor and Director of the National Drug Research Institute at Curtin University, Australia, and works part time as a clinical psychologist. He has published widely on drugs, health and the law and provided advice to a range of government and private organizations on evidence-based drug policy and other drug issues.
Chris Wilkins is Associate Professor and is the leader of the drug research team at SHORE & Whariki Research Centre, Massey University, New Zealand. He has researched drug trends, drug markets and drug policy change. Dr Wilkins has been an invited speaker at international meetings in Europe, the United States and Australia.
Simon Lenton is a Professor and Director of the National Drug Research Institute at Curtin University, Australia, and works part time as a clinical psychologist. He has published widely on drugs, health and the law and provided advice to a range of government and private organizations on evidence-based drug policy and other drug issues.
Chris Wilkins is Associate Professor and is the leader of the drug research team at SHORE & Whariki Research Centre, Massey University, New Zealand. He has researched drug trends, drug markets and drug policy change. Dr Wilkins has been an invited speaker at international meetings in Europe, the United States and Australia.
Content
Introduction; PART I : THE NEW LEGAL CANNABIS MARKETS; 1.The uneven repeal of cannabis prohibition in the United States; 2.Practical lessons learned from the first years of the regulated recreational cannabis market in Colorado; 3.Recreational marijuana legalization in Washington State: benefits and harms; 4.A century of cannabis control in Canada: a brief overview of history, context and policy frameworks from prohibition to legalization; 5.Uruguay: the first country to legalize cannabis; PART II: GENERAL MODELS OF REFORM; 6.Cannabis decriminalization policies across the globe; 7."More than just counting the plants": different home cannabis cultivation policies, cannabis supply contexts and approaches to their evaluation; 8. City-level policies of regulating recreational cannabis in Europe: from pilot projects to "local customization"?; PART III: LESSONS FROM ALCOHOL, TOBACCO AND LEGAL HIGHS 9.Lessons learned from the alcohol regulation perspective; 10.Lessons from tobacco regulation for cannabis product regulation; 11.How not to legalize cannabis: lessons from New Zealand's experiment with regulating "legal highs"; PART IV: EARLIER INNOVATIONS IN CANNABIS LAW REFORM; 12.Coffeeshops in the Netherlands: regulating the front door and the back door; 13. Cannabis social clubs in Spain: recent legal developments; 14.Swiss cannabis policies; 15. The Australian experience and opportunities for cannabis law reform; 16.Cannabis policy reform: Jamaica's experience; PART V : NEW CANNABIS LEGALIZATION PROPOSALS; 17.The risks of cannabis industry funding of community and drug treatment services: Insights from gambling; 18.Insights for the design of Cannabis Social Club regulation; Conclusion